<?xml version="1.0" encoding="UTF-8"?>
<p>Targeting host cell processes provides an attractive broad-spectrum strategy because they are often employed by multiple viruses and, in addition, they are less prone to develop drug resistance [
 <xref rid="B86-pharmaceuticals-12-00101" ref-type="bibr">86</xref>]. These host-acting inhibitors can be directed to any molecule or pathway implicated in the different steps of the viral life cycle, from binding, entry and fusion, to the formation of the replication complex, viral maturation, and egress. 
</p>
